Skoči na glavni sadržaj

Medicina Fluminensis, Vol. 55 No. 3, 2019.

Pregledni rad

https://doi.org/10.21860/medflum2019_221600

Diabetes mellitus and DPP IV/CD26 Inhibitors

Lara Batičić orcid id orcid.org/0000-0002-2837-4157 ; Zavod za medicinsku kemiju, biokemiju i kliničku kemiju, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Lara Ivanović ; Studentica Medicinskog fakulteta Sveučilišta u Rijeci, Rijeka, Hrvatska
Antonijo Grčić ; Student Medicinskog fakulteta Sveučilišta u Rijeci, Rijeka, Hrvatska
Ester Pernjak Pugel ; Zavod za histologiju i embriologiju, Medicinski fakultet, Sveučilište u Rijeci, Rijeka, Hrvatska
Jadranka Varljen ; Zavod za medicinsku kemiju, biokemiju i kliničku kemiju, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska
Dijana Detel orcid id orcid.org/0000-0001-8986-0880 ; Zavod za medicinsku kemiju, biokemiju i kliničku kemiju, Medicinski fakultet Sveučilišta u Rijeci, Rijeka, Hrvatska

Puni tekst: hrvatski pdf 1.432 Kb

str. 200-214

preuzimanja: 2.026

citiraj

Sažetak

Diabetes (lat. Diabetes mellitus) is a chronic metabolic disease characterized by persistent hyperglycaemia and carbohydrate, fat and protein metabolism disorders. Diabetes could be classified as type 1 or 2, gestational diabetes, and other, less common forms. Due to a prominent increase in the incidence and prevalence of the disease, it represents a significant public-health problem, being between the ten leading causes of mortality in the world. Dipeptidyl peptidase IV, or molecule CD26 (DPP IV / CD26, EC 3.4.14.5), is an ubiquitous multifunctional transmembrane and soluble glycoprotein and serine peptidase, recognized as a crucial factor in maintaining glucose homeostasis, primarily due to the ability to hydrolize incretins. Scientific and clinical studies have shown a high therapeutic potential of DPP IV/CD26 inhibitors in diabetic patients. This review focuses on various aspects of type 1 and 2 diabetes and newer treatment approaches for these diseases, with a special focus on DPP IV/CD26 inhibitors as effective therapeutic options.

Ključne riječi

CD26; Diabetes mellitus; dipeptidyl peptidase IV; DPP IV/CD26 inhibitors

Hrčak ID:

221600

URI

https://hrcak.srce.hr/221600

Datum izdavanja:

1.9.2019.

Podaci na drugim jezicima: hrvatski

Posjeta: 3.936 *